tradingkey.logo

Health Rounds: Eligibility criteria limits minority patient access to precision cancer drugs

ReutersJan 9, 2025 8:43 PM

Health Rounds is published on Tuesdays and Thursdays. Think your friend or colleague should know about us? Forward this newsletter to them. They can also subscribe here.

By Nancy Lapid

- Hello, Health Rounds Readers! We once again return to the theme of racial inequities in U.S. healthcare, this time regarding access to newer precision cancer treatments. We also cover early data on a promising new approach to tackling the Ebola virus.

Cancer treatment criteria disadvantage minority patients

Eligibility for treatment with the latest cancer drugs is often determined by genetic mutations in tumors, criteria that leave minority patients at a disadvantage due to their under-representation in clinical trials, a new study found.

The earlier studies that identified the gene mutations, or specific cancer biomarkers, targeted by these drugs were primarily done in patients of European ancestry, researchers reported on Thursday in JAMA Oncology.

Under-representation of non-European ancestral groups in research databases and biobanks has stymied identification of biomarkers that are rare overall but common in minority groups, the researchers said.

Studying data on 59,433 cancer patients, they found significant differences between various ancestry groups in biomarker-based eligibility for treatment with precision oncology drugs, which are targeted to the DNA signature of an individual patient's tumor.

Patients with African ancestry were least likely to have the biomarkers that would make them eligible for precision oncology drugs, but those of East Asian and South Asian ancestries were also less likely to benefit from these personalized therapies, said study leader Debyani Chakravarty of Memorial Sloan Kettering Cancer Center in New York.

These genetic ancestry-based differences in biomarker-based eligibility for cancer treatments do not entirely explain the care access disparities faced by historically marginalized populations in the United States, Chakravarty said.

“Other contributors to these disparities exist, and many researchers... are actively working to identify and address them.”

New nanobody approach shows early promise against Ebola

A new method for attacking the Ebola virus using tiny antibodies derived from alpacas is showing promise in the laboratory, researchers reported in PLOS Pathogens.

The researchers developed two new Ebola virus nanobody inhibitors. Nanosota-EB1 blocks the ability of the virus to attach itself to cells, while Nanosota-EB2 targets a critical component of the virus necessary for cell entry, halting its spread.

In laboratory experiments in mice, the two nanobodies reduced the Ebola fatality rate to 16%, from 83% without treatment.

Ebola belongs to a class of viruses called filoviruses, for which there are two U.S. approved human antibody drugs - Ebanga from Ridgeback Biotherapeutics and Inmazeb from Regeneron Pharmaceuticals REGN.O.

The researchers from the University of Minnesota said nanobodies would offer advantages such as easier production, transportation, and storage and the potential for intranasal administration. They can also be rapidly adapted to target other viral variants or related viruses, the researchers added.

The study was carried out with funding from the U.S. National Institutes of Health.

(Reporting by Nancy Lapid; editing by Bill Berkrot)

((Nancy.Lapid@thomsonreuters.com))

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

tradingkey.logo
tradingkey.logo
Intraday Data provided by Refinitiv and subject to terms of use. Historical and current end-of-day data provided by Refinitiv. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
* References, analysis, and trading strategies are provided by the third-party provider, Trading Central, and the point of view is based on the independent assessment and judgement of the analyst, without considering the investment objectives and financial situation of the investors.
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.